PDE IV inhibitors
    1.
    发明授权
    PDE IV inhibitors 失效
    PDE IV抑制剂

    公开(公告)号:US07115623B2

    公开(公告)日:2006-10-03

    申请号:US10480378

    申请日:2002-06-11

    IPC分类号: C07D471/02 A61K31/44

    CPC分类号: C07D471/04

    摘要: The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1): wherein A is methylene, lower alkylmethylene, carbonyl, etc., Y is a 5- or 6-membered heteroaryl group containing one or two heteroatoms selected from nitrogen, sulfur and oxygen, Z is i) a fused ring in which any of 5- or 6-membered heteroaryl groups is fused to a benzene ring, or ii) a phenyl group which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of nitro, amino, an amino nitrogen-containing group, etc., provided that when A is methylene, Y is a 5- or 6-membered heteroaryl group selected from the group consisting of pyrrolyl, pyridyl, etc., and Z is a phenyl group which may be unsubstituted or substituted, the substituent on said phenyl group is amino, or an amino nitrogen-containing group; or a pharmaceutically acceptable salt thereof, possesses excellent PDE IV inhibition and is useful as a pharmaceutical drug, preferably an anti-asthmatic, etc.

    摘要翻译: 目的是提供选择性PDE IV抑制剂,其具有优异的抗哮喘特征,具有优异的安全性。 式(1)的化合物:其中A是亚甲基,低级烷基亚甲基,羰基等,Y是含有一个或两个选自氮,硫和氧的杂原子的5或6元杂芳基,Z是i) 其中5-或6-元杂芳基中的任一个与苯环稠合的稠合环,或ii)可以是未取代的或任选被一个或多个选自以下的成员取代的苯基:硝基,氨基, 氨基含氮基团等,条件是当A是亚甲基时,Y是选自吡咯基,吡啶基等的5或6元杂芳基,Z是可以是 未取代或取代的,所述苯基上的取代基是氨基或氨基含氮基团; 或其药学上可接受的盐具有优异的PDE IV抑制作用,并且可用作药物,优选抗哮喘等。

    1,8-naphthyridin-2(1H)-one derivatives
    2.
    发明授权
    1,8-naphthyridin-2(1H)-one derivatives 失效
    1,8-二氮杂萘-2(1H) - 酮衍生物

    公开(公告)号:US06642250B2

    公开(公告)日:2003-11-04

    申请号:US09889107

    申请日:2001-07-11

    IPC分类号: A61K3144

    CPC分类号: C07D471/04

    摘要: The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1): wherein: A is an unsubstituted or optionally substituted 5 or 6 membered heteroaryl group or a fused benzene ring in which any of the above-defined heteroaryl groups is fused to a benzene ring, B is carbon or nitrogen, R1 is hydrogen, lower alkyl, trifluoromethyl, hydroxyl, lower alkoxy, a residue derived from a carboxylic acid or a derivative thereof, amino, or an amino nitrogen-containing group, R2 is hydrogen, halogen, cyano, nitro, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, trifluoromethyl, hydroxyl, lower alkoxy, a residue derived from a carboxylic acid or a derivative thereof, amino, or an amino nitrogen-containing group, and m is an integer of from 1 to 8, both inclusive; or a pharmaceutically acceptable salt thereof possesses selective PDE IV inhibition and is useful as a pharmaceutical drug, preferably an anti-asthmatic, etc.

    摘要翻译: 目的是提供选择性PDE IV抑制剂,其具有优异的抗哮喘特征,具有优异的安全性。 式(1)的化合物:其中:A是未取代或任选取代的5或6元杂芳基或稠合苯环,其中任何上述定义的杂芳基与苯环稠合,B是碳或 氮,R 1是氢,低级烷基,三氟甲基,羟基,低级烷氧基,衍生自羧酸或其衍生物的氨基,氨基或氨基含氮基团,R 2是氢,卤素, 氰基,硝基,低级烷硫基,低级烷基亚磺酰基,低级烷基磺酰基,三氟甲基,羟基,低级烷氧基,衍生自羧酸或其衍生物的氨基,氨基或氨基含氮基团,m为1〜 8,均包括在内;或其药学上可接受的盐具有选择性的PDE IV抑制作用,并且可用作药物,优选抗哮喘等。

    Pyrazolonaphthyridine derivative
    3.
    发明申请
    Pyrazolonaphthyridine derivative 有权
    吡唑并萘啶衍生物

    公开(公告)号:US20060040972A1

    公开(公告)日:2006-02-23

    申请号:US10533806

    申请日:2003-11-05

    IPC分类号: A61K31/4745 C07D471/14

    摘要: The target is to provide PDE IV inhibitors which have a highly potent anti-asthmatic and/or COPD-prophylactic/therapeutic profile with unexpectedly excellent safety. A compound of the formula (1): wherein A is phenyl, pyridyl, 1-oxypyridyl, or thienyl, which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of hydroxyl, halogen, cyano, nitro, lower alkyl, lower alkoxy, lower alkylcarbonyloxy, amino, carboxyl, lower alkoxycarbonyl, carboxy-lower alkylene, lower alkoxycarbonyl-lower alkylene, lower alkylsulfonyl, lower alkylsulfonylamino, and ureido; R1 is a group selected from the group consisting of hydrogen, hydroxyl, halogen, cyano, nitro, lower alkoxy, amino, carboxyl, and lower alkoxycarbonyl; R2 is hydrogen or lower alkyl; and m is an integer of 1 to 3; or a pharmaceutically acceptable salt thereof, possesses highly excellent PDE IV-specific inhibitory actions and is useful as an anti-asthmatic drug and/or a prophylactic/therapeutic drug for COPD with high safety.

    摘要翻译: 目标是提供具有非常有效的抗哮喘和/或COPD预防/治疗特征的PDE IV抑制剂,具有出人意料的极好的安全性。 式(1)的化合物:其中A是苯基,吡啶基,1-氧代吡啶基或噻吩基,其可以是未取代的或任选地被一个或多个选自羟基,卤素,氰基,硝基,低级 烷基,低级烷氧基,低级烷基羰基氧基,氨基,羧基,低级烷氧基羰基,羧基 - 低级亚烷基,低级烷氧基羰基 - 低级亚烷基,低级烷基磺酰基,低级烷基磺酰基氨基和脲基。 R 1是选自氢,羟基,卤素,氰基,硝基,低级烷氧基,氨基,羧基和低级烷氧基羰基的基团。 R 2是氢或低级烷基; m为1〜3的整数。 或其药学上可接受的盐具有非常优异的PDE IV特异性抑制作用,并且可用作具有高度安全性的抗哮喘药和/或用于COPD的预防/治疗药物。

    Pyrazolonaphthyridine derivatives
    4.
    发明申请
    Pyrazolonaphthyridine derivatives 审中-公开
    吡唑并萘啶衍生物

    公开(公告)号:US20100093782A1

    公开(公告)日:2010-04-15

    申请号:US12585430

    申请日:2009-09-15

    摘要: The target is to provide PDE IV inhibitors which have a highly potent anti-asthmatic and/or COPD-prophylactic/therapeutic profile with unexpectedly excellent safety. A compound of the formula (1): wherein A is phenyl, pyridyl, 1-oxypyridyl, or thienyl, which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of hydroxyl, halogen, cyano, nitro, lower alkyl, lower alkoxy, lower alkylcarbonyloxy, amino, carboxyl, lower alkoxy-carbonyl, carboxy-lower alkylene, lower alkoxycarbonyl-lower alkylene, lower alkylsulfonyl, lower alkylsulfonyl-amino, and ureido; R1 is a group selected from the group consisting of hydrogen, hydroxyl, halogen, cyano, nitro, lower alkoxy, amino, carboxyl, and lower alkoxycarbonyl; R2 is hydrogen or lower alkyl; and m is an integer of 1 to 3; or a pharmaceutically acceptable salt thereof, possesses highly excellent PDE IV-specific inhibitory actions and is useful as an anti-asthmatic drug and/or a prophylactic/therapeutic drug for COPD with high safety.

    摘要翻译: 目标是提供具有非常有效的抗哮喘和/或COPD预防/治疗特征的PDE IV抑制剂,具有出人意料的极好的安全性。 式(1)的化合物:其中A是苯基,吡啶基,1-氧代吡啶基或噻吩基,其可以是未取代的或任选地被一个或多个选自羟基,卤素,氰基,硝基,低级 烷基,低级烷氧基,低级烷基羰基氧基,氨基,羧基,低级烷氧基 - 羰基,羧基 - 低级亚烷基,低级烷氧基羰基 - 低级亚烷基,低级烷基磺酰基,低级烷基磺酰基 - 氨基和脲基。 R 1是选自氢,羟基,卤素,氰基,硝基,低级烷氧基,氨基,羧基和低级烷氧基羰基的基团。 R2是氢或低级烷基; m为1〜3的整数。 或其药学上可接受的盐具有非常优异的PDE IV特异性抑制作用,并且可用作具有高度安全性的抗哮喘药和/或用于COPD的预防/治疗药物。

    Pyrazolonaphthyridine derivative
    5.
    发明授权
    Pyrazolonaphthyridine derivative 有权
    吡唑并萘啶衍生物

    公开(公告)号:US07608716B2

    公开(公告)日:2009-10-27

    申请号:US10533806

    申请日:2003-11-05

    摘要: The target is to provide PDE IV inhibitors which have a highly potent anti-asthmatic and/or COPD-prophylactic/therapeutic profile with unexpectedly excellent safety. A compound of the formula (1): wherein A is phenyl, pyridyl, 1-oxypyridyl, or thienyl, which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of hydroxyl, halogen, cyano, nitro, lower alkyl, lower alkoxy, lower alkylcarbonyloxy, amino, carboxyl, lower alkoxycarbonyl, carboxy-lower alkylene, lower alkoxycarbonyl-lower alkylene, lower alkylsulfonyl, lower alkylsulfonylamino, and ureido; R1 is a group selected from the group consisting of hydrogen, hydroxyl, halogen, cyano, nitro, lower alkoxy, amino, carboxyl, and lower alkoxycarbonyl; R2 is hydrogen or lower alkyl; and m is an integer of 1 to 3; or a pharmaceutically acceptable salt thereof, possesses highly excellent PDE IV-specific inhibitory actions and is useful as an anti-asthmatic drug and/or a prophylactic/therapeutic drug for COPD with high safety.

    摘要翻译: 目标是提供具有非常有效的抗哮喘和/或COPD预防/治疗特征的PDE IV抑制剂,具有出人意料的极好的安全性。 式(1)的化合物:其中A是苯基,吡啶基,1-氧代吡啶基或噻吩基,其可以是未取代的或任选地被一个或多个选自羟基,卤素,氰基,硝基,低级 烷基,低级烷氧基,低级烷基羰基氧基,氨基,羧基,低级烷氧基羰基,羧基 - 低级亚烷基,低级烷氧基羰基 - 低级亚烷基,低级烷基磺酰基,低级烷基磺酰基氨基和脲基。 R 1是选自氢,羟基,卤素,氰基,硝基,低级烷氧基,氨基,羧基和低级烷氧基羰基的基团。 R2是氢或低级烷基; m为1〜3的整数。 或其药学上可接受的盐具有非常优异的PDE IV特异性抑制作用,并且可用作具有高度安全性的抗哮喘药和/或用于COPD的预防/治疗药物。

    Heterocycle Compound, and Production Process and Application Thereof
    6.
    发明申请
    Heterocycle Compound, and Production Process and Application Thereof 失效
    杂环化合物及其制备方法及应用

    公开(公告)号:US20090131467A1

    公开(公告)日:2009-05-21

    申请号:US11991858

    申请日:2006-09-15

    CPC分类号: C07D471/14 C07D471/04

    摘要: The compound of the present invention is a novel compound which has a specific heterocycle skeleton, particularly a pyrazolonaphthyridine or pyrazoloquinoline skeleton having an organic group (e.g., a carbocycle and a heterocycle) bonding through an alkylene group at 3-position and a carbocycle bonding at 5-position and has a phosphodiesterase IV inhibitory activity. At least one of the ring (the carbocycle or the heterocycle) bonding at 3-position of the pyrazolonaphthyridine skeleton and the carbocycle bonding at 5-position may have a halogenated alkyl group and/or a halogenated alkoxy group as a substituent. Such a compound or a salt thereof is useful as a phosphodiesterase IV inhibitor and the like. According to the present invention, a novel compound having a high phosphodiesterase IV inhibitory effect can be provided.

    摘要翻译: 本发明的化合物是具有特定杂环骨架的新型化合物,特别是具有通过3-位亚烷基键合的有机基团(例如,碳环和杂环)的吡唑并萘并吡啶骨架, 具有磷酸二酯酶IV抑制活性。 在吡唑并萘啶骨架的3位键合的环(碳环或杂环)中的至少一个和在5位键合的碳环可以具有卤代烷基和/或卤代烷氧基作为取代基。 这种化合物或其盐可用作磷酸二酯酶IV抑制剂等。 根据本发明,可以提供具有高磷酸二酯酶IV抑制作用的新型化合物。

    Heterocycle compound, and production process and application thereof
    7.
    发明授权
    Heterocycle compound, and production process and application thereof 失效
    杂环化合物及其制备方法和应用

    公开(公告)号:US08193356B2

    公开(公告)日:2012-06-05

    申请号:US11991858

    申请日:2006-09-15

    CPC分类号: C07D471/14 C07D471/04

    摘要: The compound of the present invention is a novel compound which has a specific heterocycle skeleton, particularly a pyrazolonaphthyridine or pyrazoloquinoline skeleton having an organic group (e.g., a carbocycle and a heterocycle) bonding through an alkylene group at 3-position and a carbocycle bonding at 5-position and has a phosphodiesterase IV inhibitory activity. At least one of the ring (the carbocycle or the heterocycle) bonding at 3-position of the pyrazolonaphthyridine skeleton and the carbocycle bonding at 5-position may have a halogenated alkyl group and/or a halogenated alkoxy group as a substituent. Such a compound or a salt thereof is useful as a phosphodiesterase IV inhibitor and the like. According to the present invention, a novel compound having a high phosphodiesterase IV inhibitory effect can be provided.

    摘要翻译: 本发明的化合物是具有特定杂环骨架的新型化合物,特别是具有通过3-位亚烷基键合的有机基团(例如,碳环和杂环)的吡唑并萘并吡啶骨架, 具有磷酸二酯酶IV抑制活性。 在吡唑并萘啶骨架的3位键合的环(碳环或杂环)中的至少一个和在5位键合的碳环可以具有卤代烷基和/或卤代烷氧基作为取代基。 这种化合物或其盐可用作磷酸二酯酶IV抑制剂等。 根据本发明,可以提供具有高磷酸二酯酶IV抑制作用的新型化合物。

    Pyrazole derivatives and COX inhibitors containing them
    8.
    发明授权
    Pyrazole derivatives and COX inhibitors containing them 有权
    吡唑衍生物和含有它们的COX抑制剂

    公开(公告)号:US6136831A

    公开(公告)日:2000-10-24

    申请号:US402433

    申请日:1999-10-07

    摘要: The purpose is to provide anti-inflammatory agents which have potent pharmacological actions and exert a selective inhibitory activity on COX-2, thereby being expected to reduce adverse effects such as disorders in gastric mucosa. The present invention encompasses a compound of the formula (1): wherein R.sup.1 is hydrogen or halogen, R.sup.2 and R.sup.3 are each independently hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy or lower alkanoyloxy, R.sup.4 is lower haloalkyl or lower alkyl, X is sulfur, oxygen or NH, and Y is lower alkylthio, lower alkylsulfonyl or sulfamoyl, which exerts superior anti-inflammatory activity, and highly inhibits COX-2 induced in inflamed sites, with less inhibitory action on COX-1 present in stomach, kidney, etc. Pharmaceutical agents comprising the compound of the present invention are provided as selective COX-2 inhibitors, and anti-inflammatory agents rarely accompanying adverse actions including attacks on gastric mucosa.

    摘要翻译: PCT No.PCT / JP98 / 01664 Sec。 371 1999年10月7日第 102(e)日期1999年10月7日PCT提交1998年4月10日PCT公布。 公开号WO98 / 46594 日期1998年10月22日目的是提供具有有效药理作用并对COX-2具有选择性抑制活性的抗炎剂,从而预期减少诸如胃粘膜疾病的不良反应。 本发明包括式(1)的化合物:其中R1是氢或卤素,R2和R3各自独立地是氢,卤素,低级烷基,低级烷氧基,羟基或低级烷酰氧基,R4是低级卤代烷基或低级烷基,X 是硫,氧或NH,Y是低级烷硫基,低级烷基磺酰基或氨磺酰基,其具有优异的抗炎活性,并且高度抑制炎症部位诱导的COX-2,对胃,肾中COX-1的抑制作用较小 提供包含本发明化合物的药物作为选择性COX-2抑制剂,和很少伴随不良反应(包括攻击胃粘膜)的抗炎剂。